Evaluation of Hilo® Versus Daflon® in Patients Suffering from Hemorrhoids: A Randomized, Controlled, Open-labelled, Multicentric Study

Simple item page
dc.contributor.authorDewan, Bhupeshen_US
dc.contributor.authorPrabhu, Saritaen_US
dc.date.accessioned2020-10-16T08:51:59Z
dc.date.available2020-10-16T08:51:59Z
dc.date.issued2019-08
dc.description.abstractAims: To evaluate and compare the efficacy of Hilo® and Daflon® 500 mg, in the treatment of hemorrhoids.Study Design:It is a multicentric, randomized, comparative clinical trial conducted for the period of 15 days.Place and Duration of Study:Janta Hospital and Maternity Centre, Varanasi; King George Memorial Hospital, Lucknow; Vijan Hospital and Research Centre, Nasik and Santosh Hospital, Bangalorebetween May 2018 and December 2019.Methodology:201 patients were screened and 200 patients with hemorrhoids (proctoscopy proven Grade I to III) were randomly assigned to receive either Hilo® capsules (n = 99) or Daflon® 500 mg tablets (n = 101). Assessment of hemorrhoidal symptoms was carried out in all patients on Day 7 and Day 15. Proctoscopic examination was carried out before the start of treatment i.e. on day 0 and at the end of treatment duration i.e. on day 15.Results:The patients treated with Hilo® showed a statistically significant improvement in the clinical symptoms of bleeding, pain, itching, soiling, tenesmus, irritation after defecation and constipation on day 7 and day 15 as compared to baseline. The “mean total symptom score” reduced by 4.55 ± 2.07 vs 3.44 ± 2.00; P < .0001 on day 7and 7.56 ± 2.40 vs 6.22 ± 2.55;P < .0001 on day 15 in thepatients treated with Hilo® and Daflon® respectively. In Hilo® Group, 82.83% of patients assessed that the treatment with Hilo® made them ‘A lot better’ as compared to only 48.51% in Daflon® group. In the Hilo® group 20.2% of patients’ treatment outcome was assessed as ‘Excellent’ by the investigators as compared to only 0.99% of patients in Daflon® group. No major adverse events were reported in the study with the use of either product.Conclusion:Hilo® is found to provide better reduction in clinical symptoms of patients suffering from hemorrhoids as compared to Daflon®en_US
dc.identifier.affiliationsDepartment of Medical Services, Zuventus Healthcare Ltd., Office No. 5119, Oberoi Garden Estate, Chandivali, Andheri (E), Mumbai-400 072, India.en_US
dc.identifier.citationDewan Bhupesh, Prabhu Sarita. Evaluation of Hilo® Versus Daflon® in Patients Suffering from Hemorrhoids: A Randomized, Controlled, Open-labelled, Multicentric Study. Journal of Advances in Medicine and Medical Research. 2019 Aug; 30(6): 1-12en_US
dc.identifier.issn2456-8899
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/209981
dc.languageenen_US
dc.publisherSCIENCEDOMAIN internationalen_US
dc.relation.issuenumber6en_US
dc.relation.volume30en_US
dc.source.urihttps://dx.doi.org//10.9734/JAMMR/2019/v30i630206en_US
dc.subjectHemorrhoidsen_US
dc.subjectclinical studyen_US
dc.subjectphlebotonicsen_US
dc.subjectflavonoidsen_US
dc.subjectcatechins.en_US
dc.titleEvaluation of Hilo® Versus Daflon® in Patients Suffering from Hemorrhoids: A Randomized, Controlled, Open-labelled, Multicentric Studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jammr2019v30n6pf1.pdf
Size:
239.49 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Advances in Medicine and Medical Research